Center-Authored Papers

Filters: Author is Irwin, David  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
B
Bensinger WI, Jagannath S, Vescio R, Camacho E, Wolf J, Irwin D, Capo G, McKinley M, Potts P, Vesole DH et al..  2010.  Phase 2 study of two sequential three-drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma.. British journal of haematology. 148(4):562-8. Abstract
J
Jagannath S, Durie BGM, Wolf JL, Camacho ES, Irwin D, Lutzky J, McKinley M, Potts P, Gabayan AE, Mazumder A et al..  2009.  Extended follow-up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma.. British journal of haematology. 146(6):619-26. Abstract
L
Lee SJ, Richardson PG, Sonneveld P, Schuster MW, Irwin D, San Miguel J-F, Crawford B, Massaro J, Dhawan R, Gupta S et al..  2008.  Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study.. British journal of haematology. 143(4):511-9. Abstract
R
Richardson P, Jagannath S, Hussein M, Berenson J, Singhal S, Irwin D, Williams SF, Bensinger WI, Badros AZ, Vescio R et al..  2009.  Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma.. Blood. 114(4):772-8. Abstract